Abstract:Background Pembrolizumab has been widely used in patients since its release, but information on cardiac Adverse Events (AEs) from pembrolizumab remains lacking, particularly in Japanese populations.
Aim The aim of this study is to evaluate time to onset, incidence rates, and outcomes for pembrolizumab-induced cardiac AEs in patients with cancer using the Japanese Adverse Drug Event Report database.
Method We analysed data for the period from April 2004 to March 2022. Data on cardiac AEs were extracted and rela… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.